- Company
- Generic companies win 3 out 4 patent disputes
- by Kim, Jin-Gu Dec 27, 2023 11:39am
- This year, out of 29 trial decision and verdict cases that arose as patent disputes, companies that filed a trial or lawsuit have won in 21 cases. This translates to a win rate of approximately 76% for companies challenging patents. Especially, excluding cases where the lawsuit or suit qualification was deemed ineligible, the dispute hadn’t
- Company
- Keytruda's indication expanded for early-stage lung cancer
- by Son, Hyung-Min Dec 27, 2023 06:05am
- MSD’s immuno-oncology drug Keytruda has been approved for early-stage lung cancer, totaling its indication count to 25. With the latest approval, Keytruda became the third treatment, alongside AstraZeneca’s Tagrisso and Roche’s Alecensa, that can be used as neoadjuvant and adjuvant therapy. With major lung cancer treatment now approved for ea
- Company
- LegoChem licenses out ADC technology... a KRW 2.2 tril deal
- by Son, Hyung-Min Dec 27, 2023 06:03am
- LegoChem Biosciences' TROP2 targeted antibody-drug conjugate technology has been licensed out to Janssen. By signing a total of 13 technology transfer and option agreements in the field of ADC alone this year. According to industry sources, LegoChem Biosciences signed a technology transfer agreement with Janssen on the 26th for its TROP2 targ
- Company
- Reimbursed Leclaza nears annual sales of 1T won
- by Chon, Seung-Hyun Dec 26, 2023 01:11pm
- Yuhan Corp.'s new cancer drug, Leclaza, swiftly wins reimbursement listing for its use as a first-line treatment. Following success with its second-line treatment, Leclaza received reimbursement for the first-line treatment within just six months of approval. The second-line treatment alone has generated quarterly sales of 6 billion won and
- Company
- Restrictions on new AML drug Xospata may be lifted next yr
- by Eo, Yun-Ho Dec 26, 2023 05:47am
- The acute myeloid leukemia drug Xospata has entered the last gateway to resolving its dosing cycle restrictions. According to industry sources, Astellas Korea has started drug pricing negotiations with the National Health Insurance Service for its Xospata (gilteritinib), a new drug for patients with relapsed or refractory acute myeloid le
- Company
- Fierce competition heralded in the hair loss treatment mkt
- by Nho, Byung Chul Dec 22, 2023 05:47am
- Enterobiome confirms the efficacy of akkermansia muciniphila in preclinical trial The battle between global big pharma and domestic pharma-bio companies is expected to unfold in the field of hair loss treatment. Multinational pharmaceutical companies that have succeeded in commercializing alopecia areata treatments - U.S. compan
- Company
- 30 companies do not fulfill disability employment obligation
- by Kim, Jin-Gu Dec 21, 2023 05:39am
- Twenty-nine Korean pharmaceutical and biotech companies have failed to fulfill their obligations to hire people with disabilities. The Ministry of Employment and Labor added AstraZeneca Korea to the list for 10 consecutive years and Kolon Pharmaceutical for 3 consecutive years due to their failure in fulfilling their disability hiring obli
- Company
- ‘Use of Cosentyx will rise in ankylosing spondylitis’
- by Son, Hyung-Min Dec 21, 2023 05:39am
- Reimbursement for Novartis' Cosentyx has been expanded to the first-line in ankylosing spondylitis in Korea. The rise of the new reimbursed drug option in the treatment of early ankylosing spondylitis, which is added to the existing options of tumor necrosis factor-alpha (TNF-α) inhibitors such as Humira and Remicade, is expected to increas
- Company
- One-shot Luxterna may soon receive reimbursement
- by Eo, Yun-Ho Dec 21, 2023 05:39am
- The one-shot retinal disease treatment 'Luxterna' is likely to be reimbursed soon. According to industry sources, Novartis Korea completed negotiations for Luxturna (voretigene neparvovec), a treatment for inherited retinal dystrophy (IRD), with the National Health Insurance Service on the 18th. Although the drug pricing negotiations d
- Company
- Marketability of homegrown drugs being tested in the US
- by Chon, Seung-Hyun Dec 20, 2023 05:41am
- Domestic pharmaceutical and bio companies are entering the US one after another. GC Biopharma succeeded in entering the US market with its blood product on its third try. Since last year, 3 domestically developed drugs have passed the US market gateway, starting with Hanmi Pharmaceutical and Celltrion. Until now, homegrown drugs that have entere
